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Obesity is a chronic disease with rising worldwide prevalence and largely associated with
several other comorbidities, such as cancer, non-alcoholic fatty liver disease (NAFLD),
and metabolic syndrome. Hepatic steatosis, a hallmark of NAFLD, is strongly correlated
with obesity and has been correlated with changes in the gut microbiota, which can
promote its development through the production of short-chain fatty acids (SCFAs)
that regulate insulin resistance, bile acid, choline metabolism, and inflammation. Recent
studies have suggested a controversial role for the inflammasome/caspase-1 in the
development of obesity and non-alcoholic steatohepatitis (NASH). Here, we evaluated
the role of inflammasome NLRP3 and caspases 1/11 in the establishment of obesity
and hepatic steatosis in diet-induced obese mice, correlating them with the global lipid
profile of the liver and gut microbiota diversity. After feeding wild-type, caspases 1/11,
and NLRP3 knockout mice with a standard fat diet (SFD) or a high-fat diet (HFD), we
found that the caspases 1/11 knockout mice, but not NLRP3 knockout mice, were more
susceptible to HFD-induced obesity, and developed enhanced hepatic steatosis even
under SFD conditions. Lipidomics analysis of the liver, assessed by MALDI-MS analysis,
revealed that the HFD triggered a significant change in global lipid profile in the liver of WT
mice compared to those fed an SFD, and this profile wasmodified by the lack of caspases
1/11 and NLRP3. The absence of caspases 1/11 was also correlated with an increased
presence of triacylglycerol in the liver. Gut microbial diversity analysis, using 16S rRNA
gene sequencing, showed that there was also an increase of Proteobacteria and a higher
Firmicutes/Bacteroidetes ratio in the gut of caspases 1/11 knockout mice fed an HFD.
Overall, mice without caspases 1/11 harbored gut bacterial phyla involved with weight
gain, obesity, and hepatic steatosis. Taken together, our data suggest an important role
for caspases 1/11 in the lipid composition of the liver and in the modulation of the gut
microbial community composition. Our results further suggest that HFD-induced obesity
and the absence of caspases 1/11 may regulate both lipid metabolism and gut microbial
diversity, and therefore may be associated with NAFLD and obesity.
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INTRODUCTION
Obesity has reached epidemic proportions globally according
to the World Health Organization, since the number of obese
individuals has been dramatically increasing worldwide. Obesity
is defined as abnormal or excessive fat accumulation that presents
a significant danger to health, increasing the risk of type 2
diabetes, hypertension, and hyperlipidemia, among others. This
metabolic disorder results from an imbalance in energy intake,
energy expense, and fat aggregation (1). Progression of obesity
is followed by the development of a chronic inflammation
promoted by the white adipose tissue and the influx of
macrophages and T cells in this tissue.
Among the several factors related to the progression and
pathogenesis of obesity, many studies have speculated about
the role of gut microbiota and non-alcoholic fatty liver disease
(NAFLD). The gut microbiome is central to the maturation and
development of mucosal and systemic immunity, the protection
of the host against pathogens, and the conservation of intestinal
epithelial homeostasis (2). The gut microbiota is at the interface
of host nutrition, genetics, and energy balance. Alterations
in gut microbial diversity, also termed dysbiosis, have been
associated with the development of obesity, and associated
metabolic conditions.
Intestinal dysbiosis is characterized by significant shifts in
microbial composition, abundance, diversity, metabolism, and
function (3). This state can result from a variety of conditions:
intestinal infection, altered host genetics, inflammation, and
dietary changes (4, 5). In obesity, the overall composition of
the gut microbiota has been reported as altered in several
studies in animal models and human subjects, with an increase
in the Firmicutes/Bacteroidetes (F/B) ratio in genetically obese
mice (ob/ob) (6) and in mice fed a high-fat diet (HFD) (7).
Moreover, germ-free (GF) mice presented reduced levels of
total body fat relative to conventionally raised (CONV-R) mice.
Additionally, the transfer of the gut microbiota from CONV-
R to GF mice increased the body fat content by 60% and
insulin resistance of the host (8). Comparisons of the metabolite
profiles of mice fed a HFD and low-fat diet (LFD) identified
some microbial-derived metabolites that are depleted after
HFD (9).
The characteristic inflammatory status in obesity triggers the
release of pro-inflammatory cytokines, chemokines, and pro-
inflammatory fatty acids (10). Two of the pro-inflammatory
cytokines already linked to obesity are IL-1β and IL-18 (11).
These cytokines are a direct product of inflammasome activation
by the cleavage of caspase 1. Inflammasomes are multi-
protein platforms containing one of many upstream NOD-
like receptor (NLR) proteins, which may or may not contain
the adaptor protein apoptosis-associated speck-like protein
containing CARD (ASC), and the effector caspase 1 (12). Caspase
1 knockout mice kept under HFD has been shown to develop
obesity due to reduced IL-18 levels (13). Murine and human
models revealed that increased NLRP3 expression in adipose
tissue is linked to obesity-associated insulin resistance (14). Thus,
in the context of obesity and NAFLD, inflammasomes not only
orchestrate host defense mechanisms during infection, but their
contribution to innate responses also includes the control of the
gut microbiota composition (15).
A complex balance exists among diet, gutmicrobiota diversity,
obesity, and the regulation of immune and inflammatory
responses. There is a growing concern that diet-induced changes
in the gut microbiota can directly contribute to the growing
epidemics of metabolic diseases. However, the mechanisms
through which gut bacteria respond to dietary changes and
how other inflammatory complexes alter this response remain
unclear. Thus, in this work, we aimed to elucidate how the
absence of caspases 1/11 can influence the effects of HFD-
induced obesity in mouse models by exploring changes in gut
microbial composition and liver global lipid profile.
MATERIALS AND METHODS
Animal Work
Wild-type (WT) 8-week-old female mice C57BL/6J were used,
as well as knockouts for caspase 1/11 (Caspases 1/11−/−) and
NLRP3 (Nlrp3−/−). Caspases 1/11−/− and Nlrp3−/− mice were
kindly provided by Prof. Dario S. Zamboni from the University
of São Paulo–Ribeirão Preto. Mice were kept in the Laboratory
Animal Breeding and Experimental Facility of the Institute of
Biological Sciences of the University of Brasília throughout the
experiments and the absence of NLRP3 and caspase 1 and 11
was periodically checked by genotyping. Animals were housed
under 12-h light–dark cycles at a controlled temperature (23◦C±
2◦C), with water and food ad libitum. Sixteen animals from each
genotype (WT, Caspases1/11−/−, orNlrp3−/−) were randomized
into 2 groups (n = 8 per group) and treated for 90 days with
standard fat diet (SFD) or high fat diet (HFD). The SFD was
AIN-93G (16) (17 kcal% fat – 83% unsaturated fat and 16%
saturated fat). The HFD was AIN-93G modified (45 kcal% fat –
59% unsaturated fat and 41% saturated fat).
Histological Analysis
Livers were fixed in 3.7% formaldehyde overnight at room
temperature immediately after euthanasia. Organs were
paraffinized and sectioned at 5-µm thickness by a microtome.
The slides were stained with hematoxylin and eosin (HE)
(Sigma) following standard procedures (17). Sections were
examined by light microscopy Zeiss Lab. A1 Axiocam
105 color and photomicrographs were scanned using the
ZEN program from Zeiss. Steatosis was numerically scored
following semi-quantitative pathological standards using ImageJ
software (18).
Mass Spectrometry Analysis
Lipids Extraction Procedure From Livers
We used a modification of the Bligh-Dyer protocol for lipid
extraction method (19). Briefly, the liquid was suspended
in 150 µl of Milli-Q water. Then, 190 µl of chloroform
and 375 µl of methanol were added and the mixture was
vortexed for 5min. Then, 190 µl of chloroform and 150 µl
of Milli-Q water were added and vortexed for 1min, and the
mixture was centrifuged at 14,000×g for 5min to induce phase
separation. The lower organic layer was collected, concentrated
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in a Speed-Vac apparatus, and reconstituted into 100 µl of
a chloroform/methanol (1:1) solution. The mixture was then
spotted (1 µl droplet) onto a MALDI plate and air-dried. Then,
1 µl of 2,5-dihydroxybenzoic acid (DHB) matrix, prepared at
a concentration of 10mg ml−1 in methanol, was spotted over
the dried sample. The TOF analyzer calibration and tuning were
performed using a phospholipid mixture composed of DOPE,
DMPG, DPPA, and DPPS for lipid analysis.
MALDI-MS Analysis
MALDI-MS was performed on a Bruker Autoflex III MALDI–
TOF/TOF mass spectrometer equipped with a 334-nm smart
beam laser. The spectrum was acquired in the TOF linear mode
and in the positive ionization mode with a delayed extraction of
260 ns at 20 kV accelerating voltage. Each spectrumwasmanually
collected as an average of 5,000 laser shots (1,000 laser shots at
five different spot positions). Laser energy was set just at 70%.
A range of m/z 600–1,200 was used to obtain the lipid profiles.
Spectra were acquired in triplicate and the AutoExecute tool of
Flexcontrol acquisition software was used (Version 2.4; Bruker-
Daltonik GmbH) for processing. Only ions with an S/N ratio >3
were considered.
Multivariate Analysis of MALDI-MS Data
The analysis of MALDI data was done via three distinct
steps: (1) pre-processing, (2) processing, and (3) statistical
analysis. Raw spectra were pre-processed in the FlexAnalysis
software (Bruker-Daltonik) for matrix background removal,
alignment of the spectra scale, ion selection with an S/N ratio
>3, and normalization of abundances. Data processing was
performed before multivariate analysis for the lipid profiles in the
MetaboAnalyst 3.0 (version software). The uploaded files (.csv
format) comprised a list of ions (m/z and relative abundances).
The ions were realigned within a tolerance of m/z 0.4 (0.4 Da)
to remove ions that appear in less than half of the samples in
each group. The presence of missing values or ions with constant
values (i.e., all zeros) was checked and data filtering using relative
standard deviation (RSD) was applied to remove variables close
to baseline or detection limit as variables that are near-constant
values. Then, the relative abundance of ion was normalized
by autoscaling (mean-centered and divided by the standard
deviation of each variable) as preprocessing to multivariate
analysis. Both unsupervised and supervised statistical approaches
were applied. Principal component analysis (PCA) and partial
least squares–discriminant analysis (PLS-DA) were performed
on the data using the MetaboAnalyst (version 3.0 software)
(20) to discriminate the samples based on their lipid profiles.
To determine independent factors and relevant ions within the
experiment, we used Variable Importance in Projection (VIP)
from PSL-DA analysis. All data were obtained from a non-
parametric analysis.
Annotation of Lipids
The major discriminant lipids of the MALDI-MS analysis were
selected out of the multivariate analysis and their annotation
was made according to the exact mass (m/z) of the protonated
ion and their fragmentation spectra. The lipid data (.txt format)
comprised am/z and relative abundance list of the ions obtained
from MS and MS/MS spectra were uploaded to Metlin (http://
metlin.scripps.edu), ChemSpider (www.chemspider.com), and
MassBank (http://www.massbank.jp/); The Human Metabolome
DataBase—HMDB (21) and the LIPID Metabolites And
Pathways Strategy—LIPID MAPS R© (Wellcome Trust) spectra
database were used to annotate the lipids.
Gut Microbial Analysis
DNA Extraction and Amplification of V4 Region
Mice fecal samples from all groups were collected at the end of
treatment and immediately stored at −80◦C. High-throughput
sequencing of the V4 region of the 16S ribosomal RNA (rRNA)
gene was performed to characterize the distal gut microbiota
composition, according to published works (22). Each sample
was subjected to DNA extraction with MoBio PowerSoil DNA
isolation kit protocol (MoBio, Carlsbad, CA, USA), before
quantification with a Nanodrop. The V4 region of the 16S rRNA
gene was PCR-amplified in triplicate with custom barcoded
universal bacterial primers using the following protocol: 94◦C
for 3min, 35 cycles of 94◦C for 45 s, 50◦C for 30 s, and 72◦C for
90 s, with a final extension at 72◦C for 10min (4), and sequenced
on an Illumina HiSeq platform at the McGill University and
Genome Quebec Innovation Center. The quality of the run was
analyzed on a 1.5% agarose gel, and controls consisted of the PCR
reaction without the DNA template. 16S rRNA gene sequences
were analyzed using the QIIME software package (23).
Statistical Analysis
Results are reported as mean ± SD, or mean ± SEM unless
otherwise noted. Differences among the groups were compared
using ANOVA with Turkey post-test for multiple comparisons
and Student’s t test with Bonferroni corrections when there were
only two groups. All statistical analysis was performed using
GraphPad PRISM 6 or QIIME software. p-values are represented
by asterisks: p ≤ 0.05 (∗), p ≤ 0.01 (∗∗), p ≤ 0.001 (∗∗∗),
and p ≤ 0.0001 (∗∗∗∗).
Ethics Approval Statement
This study was approved by the Committee for Ethics in Animal
Use of the Institute of Biological Sciences of the University of
Brasilia, UnBDoc n◦52306/2014.
RESULTS
The Absence of Inflammasome
Components Directly Influences Weight
Gain Under a HFD
To investigate the influence of inflammasome components in
inducing obesity in response to HFD, C57/BL6 WT, Caspases
1/11−/−, and Nlrp3−/− mice were submitted to SFD or HFD for
3 months, with weekly monitoring of weight gain (Figure 1A).
All animals fed the HFD showed an increase in weight
(Figures 1C,D). This increase was faster and more pronounced
in mice lacking caspases 1 and 11, with a significant increase
in the final weight of Caspases 1/11−/− mice compared to
the WT mice (Figure 1C). The absence of NLRP3 protein did
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not induce weight gain compared to WT mice, as WT mice
presented a greater weight than Nlrp3−/−, despite not being
significant (Figure 1D). WT, Caspases 1/11−/−, and Nlrp3−/−
mice presented no difference in SFD or HFD food intake
(Supplementary Figure S1).
Lack of Caspases 1/11 Alters Steatosis
Levels in the Liver After HFD
In the animals fed a HFD, we observed a significant increase in
the liver weight of Caspases 1/11−/− mice compared to both WT
(Figure 2A) and Nlrp3−/− mice (Figure 2B). Caspases 1/11−/−
mice fed a SFD already presented a fat accumulation in the liver,
in addition to the increased weight of the liver compared to WT
mice fed a SFD (Figure 2A). Non-alcoholic fatty liver disease
(NAFLD), which strongly correlates with obesity and metabolic
syndrome, is primarily characterized by hepatic steatosis (24).
To assess whether the increased liver weight observed could be
related to fat accumulation, we evaluated the hepatic fat content
through HE staining. This histologic imaging showed that the
HFD induced fat accumulation, with features of micro- and
macro-vesicular steatosis in all genotypes.Caspases 1/11−/− mice
presented a more significant presence of liver steatosis compared
to both WT and Nlrp3−/− mice (Figures 2C–E).
HFD Changes the Pattern of Liver Global
Lipid Composition in the Absence of
NLRP3 and Caspases 1/11
To investigate the mechanisms behind the increased hepatic
steatosis in Caspases 1/11−/− mice, we investigated the liver
global lipid profile after HFD using mass spectrometry. In the
heat map obtained from the hierarchical cluster analysis (HCA)
of SFD groups (Figure 3A), we observed that the three mouse
genotypes already demonstrated a different pattern in lipid
composition, even in mice under SFD. In the WT mice under
SFD, we observed a higher abundance of ions in range m/z 600–
800, especially when compared with the Caspases 1/11−/− mice
under SFD. In the orthogonal projections to latent structures–
discriminant analysis (OPLS-DA) score plot (Figure 3C), we
observed that lipids from WT and Caspases 1/11−/− mice tend
to form two clusters under SFD, despite the first and second
components explaining less than of total variance. Comparing
WT and Nlrp3−/− mice, while there is a difference in the
abundance of some ions (Figures 3A,E), the general view from
the OPLS-DA showed an almost total overlap of the two groups.
A VIP score of >1 from the PLS-DA model was used as a
criterion to determine the discriminating lipids associated with
the differentiation of the three genotypes. The most relevant
lipids in the VIP score, with a score>2, from the SFD (Figure 3E)
showed a majority of triacylglycerols, followed by sphingolipids
and glucosylceramides, already from HFD (Figure 3F) showed
only of triacylglycerols for the same score.
Mice fed a HFD showed a complete change of liver global
lipid pattern, with some of the lipid content being much more
abundant in the Caspases 1/11−/− mice compared to WT, as
observed in the heat map plot (Figure 3B). Only the lipids with a
m/z of 651.53, 652, and 788 were more abundant in the WT. WT,
Caspases 1/11−/−, andNlrp3−/− mice fed a SFD were apparently
overlapped on the PLS-DA score plot (Figure 3C). However,
HFD clearly influenced the liver global lipid profile, since we
observed that WT, Caspases 1/11−/−, and Nlrp3−/− mice fed a
HFD were well-clustered on the PLS-DA score plot (Figure 3D).
This difference was even more pronounced when we compare
WT and Caspases 1/11−/− given the clear separation of two
clusters due to the highest data variance in PLS-DA (47.3%),
suggesting that absence of caspase 1 and 11 may significantly
impact the liver global lipid composition of mice specially fed a
HFD. The VIP score revealed that triacylglycerols were the most
relevant class of lipids driving these differences.
HFD Changes the Gut Microbiota
Composition in Different Ways in WT and
Caspases 1/11−/− Mice
Deficiency in the NLRP6 inflammasome pathway promotes
the progression of an altered and colitogenic gut microbial
community (25). Since intestinal microbial dysbiosis is another
factor in NAFLD pathogenesis and the liver–gut axis has
a strong link with obesity, we also investigated alterations
in the gut microbiota. We quantified microbial diversity
within each group (α-diversity), and identified that Caspases
1-11−/− mice fed a HFD presented a higher gut bacterial
diversity (Supplementary Figure 2A). This unexpected result
suggested a functional role of caspases 1 and 11 regulating
gut bacterial diversity in HFD-induced obese mice. Caspases
1/11−/− mice fed HFD harbored once again a more diversified
microbial composition compared to WT under the same diet
(Supplementary Figure 2B).
We then compared the groups with each other (β-diversity),
providing a measure of distance and dissimilarity among
samples. Analyzing the effects of diet on Caspases 1-11−/−
mice only, our data suggest clustering of microbial communities
according to diet (Figures 4A,B), considering weighted or
unweighted Unifrac. However, if we focus on the weighted
Unifrac, which takes into consideration the relative abundance of
the bacterial taxa, limiting the impact of low abundance bacteria,
we could better associate it with a percentage of variance found
in the PCA plot (Figures 4C,D). If we focus on the effects of the
absence of caspases 1 and 11 after a HFD compared to WT mice,
we observed a significant difference in the β-diversity between
these groups (Figures 4E,F). In this latter case, the clustering is
more evident with the unweighted Unifrac, suggesting that the
presence or absence of certain bacterial taxa is more important
than their relative abundance (Figures 4G,H).
Consistent with previous reports (26), our taxonomic
analysis identified the Firmicutes, Bacteroidetes, Proteobacteria,
Verrucomicrobia, and Actinobacteria as the most abundant phyla
in mice fed with both types of diets (Figures 5A,B). A significant
change in bacterial community composition at the phylum level
was observed in the Caspases 1/11−/− mice fed a HFD compared
to Caspases 1/11−/− fed a SFD. Caspases 1/11−/− mice fed
a SFD had highest levels of Firmicutes (47.7%), followed by
Bacteroidetes (33.8%), Proteobacteria (9.2%), Verrucomicrobia
(3.2%), and Actinobacteria (1.1%), whereas Caspases 1/11−/−
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FIGURE 1 | Establishment of high-fat-diet-induced obesity. WT, caspase-1/11−/− and Nlpr3−/− mice were fed SFD (17% fat) or HFD (45% fat) for 90 days. The
weight gain curve was fitted with the weekly weighing of the animals (A,C). Weight of the animals at the final of treatment (B,D) and abdominal fat (E). ANOVA test
was applied, the bars representing confidence interval of 95% (****p < 0.0001).
mice fed a HFD had increased levels of Firmicutes (62.6%),
Proteobacteria (13.3%), and Verrucomicrobia (6.8%), and lower
levels of Bacteroidetes (16.4%) and Actinobacteria (0.5%). We
also observed alterations between the WT and Caspases 1/11−/−
mice fed a HFD, with 54% Firmicutes, 29.4% Bacteroidetes, 3.8%
Proteobacteria, 10.9% Verrucomicrobia, and 1.5% Actinobacteria.
Caspases 1/11−/− mice fed a HFD presented a higher
Firmicutes/Bacteroidetes ratio (F/B), equal to 3.81, compared to
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FIGURE 2 | Weight of organs and hepatic steatosis development. WT, caspase-1/1−/− and Nlpr3−/− mice were fed SFD (17% fat) or HFD (45% fat) for 90 days; after
treatment, the liver was collected. Weight of liver (A,B) and hematoxylin and eosin staining of the liver (C) after treatment. Hepatic steatosis scores (D,E) were
determined with semi-quantitative pathological standards. ANOVA test was applied, the bars representing confidence interval of 95% (*p < 0.05, **p < 0.01, ***p <
0.005, and ****p < 0.0001).
WT mice where F/B were 1.84. This was consistent with the
highest weight gain observed in Caspases 1/11−/− mice fed a
HFD (Figure 1) and previous reports (6). The Caspases 1/11−/−
mice fed a SFD, which also presented initial liver steatosis,
showed higher amounts of Proteobacteria, a phylum already
associated with obesity and NASH (27).
At the family level, we also observed differences when
analyzing the effect of the HFD in the Caspases 1/11−/− and
WT mice (Figures 5C,D). The levels of the Verrucomicrobiaceae
family after HFD decreased from 10.9% in WT mice to 6.8%
in Caspases 1/11−/− mice. The Erysipelotrichaceae family also
decreased in Caspases 1/11−/− mice fed a HFD (1%) compared
to WT mice under the same diet (6.4%). A similar event was
also observed for the Lactobascillaceae in the Caspases 1/11−/−
fed a HFD mice (1.2%) compared to WT mice fed a HFD (4%).
In contrast, the Ruminococcaceae family increased in Caspases
1/11−/− mice fed a HFD (14.4%) compared to WT under the
same diet (8.5%). Likewise, Helicobacteraceae increased from
1.3% in Caspases 1/11−/− mice fed a HFD compared to 10.9%
in WT mice fed a HFD.
There was no significant difference in overall β-diversity
when we analyzed Caspases 1/11−/− mice fed a SFD or HFD.
However, some specific families were significantly different
in mice fed each diet. We observed a decrease of the S24-
7 and Lactobascillaceae (Figures 5E,F) and an increase of the
Ruminococcaceae families (Figure 5G) in the Caspases 1/11−/−
mice fed a HFD compared to the same mice fed a SFD. However,
there was no significant difference for Erysipelotrichaceae,
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FIGURE 3 | MS/MS analysis of lipid composition in the liver. Heat map, with a color-code thermometer indicating the relative concentrations of metabolites on each
group: WT, caspase-1/11−/−, and Nlpr3−/− mice fed SFD (17% fat) or HFD (45% fat) for 90 days. Maps show the lipidomic profiles of SFD (A) and HFD (B) groups.
Orthogonal partial least squares–discriminant analysis (OPLS-DA) score plots model was constructed using MALDI lipid profiles. Each of the five animals in each group
gave rise to three samples. Plots show the lipidomic profiles animals fed with SFD (C) or HFD (D). Variable importance in projection (VIP) plot identified by partial least
squares–discriminant analysis (PLS-DA) displaying the top 10 most important features in mice fed with SFD (E) or HFD (F).
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FIGURE 4 | β-diversity of gut microbiota. Distance boxplots weighted_unifrac (A) and unweighted unifrac (B): I—All within the description, II—All between description,
III—caspase-1/11−/− SFD vs. caspase-1/11−/− SFD, IV—caspase-1/11−/− HFD vs. caspase-1/11−/− HFD, and V—caspase-1/11−/− SFD vs. caspase-1/11−/−
HFD. (C) PCoA plot weighted_unifrac and (D) PCoA plot unweighted_unifrac, blue: caspase-1/11−/−SFD, red: caspase-1/11−/− HFD. Distance boxplots
weighted_unifrac (E) and unweighted unifrac (F): I—All within the description, II—All between description, III—caspase-1/11−/− HFD vs. caspase-1/11−/− HFD,
IV—WT HFD vs. WT HFD, and V—caspase-1/11−/− HFD vs. WT HFD. (G) PCoA plot weighted_unifrac and (H) PCoA plot unweighted_unifrac, purple: WT HFD, red:
caspase-1/11−/− HFD. The tests of significance were performed using a two-sided Student’s two-sample t test, the non-parametric p-values were calculated with
(Continued)
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FIGURE 4 | Bonferroni correction. p-values for comparisons of Distance boxplots (A): I vs. II p = 0.09, I vs. III p = 1, I vs. VI p = 1, I vs. V p = 0.05, II vs. III p = 0.07,
II vs. IV p = 0.6, II vs. V p = 1, III vs. IV p = 1, III vs. V p = 0.12, and IV vs. V p = 0.54; (B): I vs. II p = 0.01, I vs. III p = 0.39, I vs. VI p = 0.89, I vs. V p = 0.01, II vs. III
p = 0.01, II vs. IV p = 1, II vs. V p = 1, III vs. IV p = 0.03, III vs. V p = 0.01, and IV vs. V p = 1; (E): I vs. II p = 0.010, I vs. III p = 1, I vs. VI p = 1, I vs. V p = 0.01, II vs.
III p = 0.1, II vs. IV p = 0.01, II vs. V p = 1, III vs. IV p = 1, III vs. V p = 0.15, and IV vs. V p = 0.01; (F): I vs. II p = 0.01, I vs. III p = 1, I vs. VI p = 1, I vs. V p = 0.01, II
vs. III p = 0.01, II vs. IV p = 0.01, II vs. V p = 1, III vs. IV p = 1, III vs. V p = 0.01, and IV vs. V p = 0.01.
Helicobacteraceae, and Verrucomicrobiaceae families in these
same conditions (Figures 5H–J).
DISCUSSION
Inflammation plays a fundamental role in the pathophysiology
of obesity, and pro-inflammatory cytokines IL-1β and IL-18 have
already been linked to this metabolic disorder. Since caspase 1
is an important regulator for the maturation of these cytokines
during inflammasome activation, many studies have started to
investigate the role of this protein in the development of obesity,
NAFLD, and other metabolic disorders. The precise role of
caspase-1 during metabolic inflammation is still unclear and
remains a little controversial due to contrasting results obtained
with the use of knockout mice (28). Previous work from Wang
et al. (13) and Kimura et al. (29) found that caspase-1 knockout
mice increased their body weight under HFD compared to WT
mice. Dixon et al. (30) demonstrated that subcutaneous and total
body adipose tissue of caspase 1 knockout mice was also higher
compared to WT mice after HFD. In our work, the bodyweight
of Caspases 1/11−/− mice fed HFD was also higher than WT,
consistent with these studies. However, the results reported by
Wang et al. (13) also demonstrated sex-specific differences in
the weight gain of caspase 1 knockout mice, with female mice
gaining weight less rapidly than their male counterparts. Our
result showed that Caspases 1/11−/− female mice gained weight
more rapidly than Wang et al. study showed, reaching 50 g after
only 3months. This potentiated effect could be due to the absence
of two caspases in our model. However, additional studies using
single caspase 11 knockout mice are necessary to confirm this.
It has been described that the increase of lipid content in the
liver, or hepatic steatosis, can be attributed to excessive intake of
alcohol or fat that is higher than the liver is able to metabolize,
thereby resulting in fat deposition inmicrovesicles in hepatocytes
(31). Steatosis increases the risk of metabolic disorders linked
with obesity such as hypertension, diabetes, dyslipidemia and
insulin resistance (32), in addition to increasing the risk of
cardiac complications and cardiovascular disease mortality (31).
A recent study showed that NLRP3 inflammasome activation is
needed for the development of hepatic steatosis, where Nlrp3−/−
mice were protected against hepatomegaly, liver injuries, and
infiltration of activatedmacrophages in a long-termmanner (33).
Our results support this, as the group of Nlrp3−/− mice under
HFD presented reduced levels of steatosis compared toWTmice.
Many patients with NAFLD end up progressing to a state
of NASH. NAFLD is the most common cause of chronic
liver disease in the United States, reaching up to 100 million
individuals, of which 25% progress to NASH (34). Trying to
understand the role of the inflammasome in NASH progression,
Henao-Mejia et al. (15) fed WT, Asc−/−, and Caspase 1−/−
mice a methionine-choline-deficient diet (MCDD). Their results
showed that Asc−/− and Caspase 1−/− mice under MCDD
presented an enhanced microvesicular and macrovesicular
hepatic steatosis. Kimura et al. (29) and Dixon et al. (30) found
that visceral and subcutaneous fat contents were increased in
Caspase 1−/− mice compared to WT. However, they did not
report an increase in the lipid content in the liver (29). Our results
showing an increase in the liver weight of Caspases 1/11−/− mice
fed a HFD, which followed the same pattern as total body weight,
support these previous studies. In addition, we also showed that
the steatosis levels in these mice are greater compared to WT
mice on the same diet. It is also important to note that even under
the SFD, Caspase 1−/− mice already presented higher steatosis
than WT.
NAFLD can be triggered by several distinct causes
involving interaction of genetic predisposition and metabolic,
inflammatory, and environmental factors (35). Among these
factors, dysregulation of gut microbiome has been linked to
the development of fatty liver disease. Interactions between
the gut microbiome and the host can drive both intestinal
homeostasis and disease. However, the mechanisms of this
cross-talk remain unclear. In the past decade, the substantial role
of the gut microbiota in the progression of obesity and NAFLD
has been identified, and the role of altered microbial metabolite
production or signaling pathways, such as bile acids or choline
metabolism, has also been highlighted (36).
Corroborating with studies of Wang et al. (13) and Kimura
et al. (29) that showed the susceptibility of Caspases 1−/− mice
to gain more weight than WT mice, we further showed here
an increase in steatosis levels in the liver and difference in
the liver global lipid profile in Caspases 1/11−/− and Nlrp3−/−
mice fed a SFD and a HFD. We identified that the obesity
state of Caspases 1/11−/− mice resulted in the most altered
phenotype, with a complete change in the liver lipid profile,
as well as a significant increase in steatosis. This is consistent
with the changes in gut microbial diversity, where we also
observe a greater proportion of Firmicutes and a relatively
lower proportion of Bacteroidetes. Kimura et al. (29) found that
HFD promoted the infiltration of inflammatory macrophages
through the CCL2/CCR2 axis, intensifying the development of
obesity in Caspases 1−/− mice. Here, we demonstrate that this
inflammatory context is enriched by alterations in the gut–
liver axis, highlighting the major changes in lipid profile and
gut microbial composition. Moreover, gut dysbiosis can lead to
endotoxemia and inflammation of the gut wall and activation
of Kupffer cells and hepatic stellate cells leading to liver injury
and inflammation (37). Backhed et al. (8) demonstrated that
microbiome transplantation from conventional mice to GF mice
produced a 57% increase in total body fat content and a 2.3-
fold increase in the content of liver triglycerides in GF mice.
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FIGURE 5 | Taxonomic analysis of the gut microbiota. WT and caspase-1/11−/− mice were fed a SFD (17% fat) or a HFD (45% fat) for 90 days. Feces from all groups
were collected and 16S rRNA gene sequencing of the V4 region was performed on the Illumina HiSeq platform to characterize the distal gut microbiota. Bar charts
represent the relative abundance of bacterial (A,B) phyla and (C,D) families in all mice according to their diet and genotype (n = 481 samples). Differences in the
abundance of a subset of bacterial families related to NAFLD found in the gut of Caspases 1-11−/− mice, according to their diet (E–J). Significance was obtained with
a t test for each bacterial taxa, the bars represent confidence interval of 95% (*p < 0.05).
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Gut colonization triggered an increase of the mRNA levels
of two key enzymes for the fatty acid biosynthetic pathway:
acetyl-CoA carboxylase (also known as Acc1) and fatty acid
synthase (also known as Fas). This may also indicate how gut
microbiota modifications could modulate liver lipid content
leading to steatosis.
While the F/B ratio can be used as an indicator of
obesity, we also report changes in pro-inflammatory and/or
putative pathogenic bacterial taxa. Proteobacteria are generally
associated with endogenous alcohol production and metabolism
in conditions of oxidative stress and are substantially increased
in steatosis and NASH patients (27). Our results show that
the Caspases 1/11−/− animals, even under SFD, presented
higher levels of Proteobacteria in their gut, which were even
higher in mice fed a HFD that showed increased weight gain
and steatosis.
The role of Verrucomicrobia and Actinobacteria in obese
is very controversial in the literature. In our study, the HFD
decreased the levels of Verrucomicrobia and Actinobacteria in
Caspases 1/11−/− mice compared to the same mice fed a SFD.
However, our results contrast with previous reports, where
Actinobacteria increased in obese subjects (38, 39). It has also
been shown that the abundance of Verrucomicrobia was reduced
in obese individuals (40), while another study showed that it
was increased in with diet-induced obese animals (39). This
demonstrates the need for further studies of gut microbiota at
the species level to deeper understand its role in obesity.
As mentioned here before, gut–liver axis cross-talk can be
highly mediated by inflammatory pathways. Our results also
suggest that inflammatory components can be directly associated
with changes in bacterial phyla observed in the mice analyzed
here. Dysbiosis involving the Lactobascillaceae family in the
context of steatosis was already described in cases where liver
diseases were associated with alcohol (41). In the present study,
we observed thatCaspases 1/11−/− mice fed a HFD presented the
most severe liver steatosis, the highest weight gain, and the lowest
amount of Lactobascillaceae in the gut microbiota. Our findings
corroborate with Wang and colleagues (42) that demonstrated
that abundance and prevalence of the Lactobascillaceae family
were reduced in the gut microbiota of NAFLD patients. Caspases
1/11−/− mice fed a HFD also presented an increase for S24-
7, a family of bacteria within the order Bacteroidales, already
correlated with obesity cases (43).
It is interesting to note that the absence of caspases 1 and
11 was sufficient to significantly change not only the liver
steatosis levels but also the composition of gut microbiota, not
regarding the role of the diets. Indeed, the Helicobacteraceae
and Ruminococcaceae families were more abundant in Caspases
1/11−/− mice fed a SFD, and this effect was intensified when
these mice were fed a HFD. The increased abundance of the
Ruminococcaceae family has also been reported in a study with
obese children (44) and women (43).
Our study suggests that the effector caspases 1 and 11 have
a function on the liver–gut axis cross-talk, playing a substantial
role in the pathogenesis of obesity. Taken together, our data
suggest an important role for caspases 1/11 in the global lipid
composition of the liver and in the modulation of the gut
microbial community composition. Our results further suggest
that HFD-induced obesity in addition to the absence of caspase
1/11 may regulate both liver global lipid metabolism and gut
microbial diversity, strongly favoring the establishment of the
NAFLD and obesity. Moreover, our data support the sense that
manipulating gut microbiota could have a therapeutic potential
to decrease the incidence and prevalence of fatty liver diseases
and obesity.
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